Daniel Benjamin Mark, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 2400 Pratt St, Durham, NC 27705
Phone (919) 668-8775
Email address mark0004@mc.duke.edu

Dr. Mark is a clinical cardiologist with the rank of Professor of Medicine (with tenure) as well as Vice Chief for Academic Affairs in the Division of Cardiology, Department of Medicine at Duke University Medical Center. He is also the Director of Outcomes Research at the Duke Clinical Research Institute. He has been on the full-time faculty at Duke since 1985. Prior to that he completed his cardiology fellowship at Duke, his residency and internship at the University of Virginia Hospital, and received his medical degree from Tufts University and his Master’s degree from Harvard. In 1998, he was given the honor of being elected to the American Society for Clinical Investigators and in 2002 he was honored by election to the Association of American Physicians. These organizations are the two most prestigious honor societies in academic medicine. In 2009, Dr. Mark was awarded the American College of Cardiology Distinguished Scientist Award.

Dr. Mark's major research interests include medical economics and quality of life outcomes, outcomes research, and quality of medical care. Currently, Dr. Mark is directing a number of outcomes analyses for ongoing clinical trials including PROMISE (anatomic versus functional testing for coronary artery disease, NIH), CABANA (catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation, NIH), ISCHEMIA (percutaneous coronary intervention versus optimal medical therapy for moderate-severe ischemia), and STICH (CABG +/- ventricular reconstruction versus medical therapy for ischemic heart disease, NIH). He was the principal author of the AHCPR Unstable Angina Guidelines and is a co-author of both the American College of Cardiology Guideline on Exercise Testing and their Coronary Stent Consensus Guideline. He is also the Editor of the American Heart Journal. Dr. Mark has published over 270 peer-reviewed articles, two books, and 80 book chapters. He lectures widely in the US, as well as in Canada, South America, and Europe.

Keywords: cost-effectiveness analysis, disease management, quality of life assessment, resource use.

Education and Training

  • M.D., Tufts University, 1978

Publications

Douglas, Pamela S., Udo Hoffmann, Manesh R. Patel, Daniel B. Mark, Hussein R. Al-Khalidi, Brendan Cavanaugh, Jason Cole, et al. “Outcomes of anatomical versus functional testing for coronary artery disease..” N Engl J Med 372, no. 14 (April 2, 2015): 1291–1300. https://doi.org/10.1056/NEJMoa1415516.

PMID
25773919
Full Text

Hess, Paul L., Sana M. Al-Khatib, Joo Y. Han, Rex Edwards, Gust H. Bardy, J Thomas Bigger, Alfred Buxton, et al. “Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials..” Circ Cardiovasc Qual Outcomes 8, no. 2 (March 2015): 179–86. https://doi.org/10.1161/CIRCOUTCOMES.114.001306.

PMID
25669833
Full Text

Cowper, Patricia A., Wenqin Pan, Kevin J. Anstrom, Padma Kaul, Lars Wallentin, Linda Davidson-Ray, Elisabet Nikolic, et al. “Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study..” J Am Coll Cardiol 65, no. 5 (February 10, 2015): 465–76. https://doi.org/10.1016/j.jacc.2014.11.034.

PMID
25660925
Full Text

Al-Khatib, Sana M., James P. Daubert, Kevin J. Anstrom, Emile G. Daoud, Mario Gonzalez, Samir Saba, Kevin P. Jackson, et al. “Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial..” J Cardiovasc Electrophysiol 26, no. 2 (February 2015): 151–57. https://doi.org/10.1111/jce.12567.

PMID
25332150
Full Text

Zeitler, Emily P., Anne S. Hellkamp, Gregg C. Fonarow, Stephen C. Hammill, Lesley H. Curtis, Adrian F. Hernandez, Hussein R. Al-Khalidi, et al. “Primary prevention implantable cardioverter-defibrillators and survival in older women..” Jacc Heart Fail 3, no. 2 (February 2015): 159–67. https://doi.org/10.1016/j.jchf.2014.09.006.

PMID
25543969
Full Text

Steinberg, Benjamin A., Sana M. Al-Khatib, Rex Edwards, JooYoon Han, Gust H. Bardy, J Thomas Bigger, Alfred E. Buxton, et al. “Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials..” Jacc Heart Fail 2, no. 6 (December 2014): 623–29. https://doi.org/10.1016/j.jchf.2014.06.007.

PMID
25306452
Full Text

Cowper, Patricia A., Shubin Sheng, Kevin J. Anstrom, Judith A. Stafford, Renato D. Lopes, Linda Davidson-Ray, Lars Wallentin, et al. “The Cost-Effectiveness of Apixaban versus Warfarin in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Study Group.” In Circulation, Vol. 130. LIPPINCOTT WILLIAMS & WILKINS, 2014.

Scholars@Duke

Patton, Kristen K., Anne S. Hellkamp, Kerry L. Lee, Daniel B. Mark, George W. Johnson, Jill Anderson, Gust H. Bardy, Jeanne E. Poole, and Jeanne E. SCD-HeFT Investigators. “Reply: circadian variations of ventricular arrhythmias and sleep-disordered breathing in HF patients..” J Am Coll Cardiol 64, no. 18 (November 4, 2014): 1968–69. https://doi.org/10.1016/j.jacc.2014.08.022.

PMID
25444153
Full Text

Felker, G Michael, Tariq Ahmad, Kevin J. Anstrom, Kirkwood F. Adams, Lawton S. Cooper, Justin A. Ezekowitz, Mona Fiuzat, et al. “Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure..” Jacc Heart Fail 2, no. 5 (October 2014): 457–65. https://doi.org/10.1016/j.jchf.2014.05.007.

PMID
25194287
Full Text

Pages